Envista Holdings Corporation (NYSE:NVST – Get Free Report) has earned a consensus rating of “Moderate Buy” from the sixteen analysts that are covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $27.0769.
Several equities research analysts have recently weighed in on the stock. William Blair raised shares of Envista from a “hold” rating to an “outperform” rating in a research report on Friday, February 6th. Mizuho upped their target price on Envista from $24.00 to $27.00 and gave the stock a “neutral” rating in a report on Tuesday, February 10th. Morgan Stanley set a $19.00 price target on Envista in a report on Friday, February 6th. Wall Street Zen raised Envista from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 26th. Finally, JPMorgan Chase & Co. raised their price objective on Envista from $22.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday, February 6th.
Check Out Our Latest Report on Envista
Envista Price Performance
Envista (NYSE:NVST – Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.During the same period in the prior year, the company earned $0.24 earnings per share. Envista’s quarterly revenue was up 15.0% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, equities research analysts anticipate that Envista will post 1 earnings per share for the current fiscal year.
Insider Activity at Envista
In related news, SVP Mischa Reis sold 9,675 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $30.00, for a total transaction of $290,250.00. Following the completion of the transaction, the senior vice president owned 32,382 shares in the company, valued at $971,460. The trade was a 23.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.66% of the company’s stock.
Hedge Funds Weigh In On Envista
Institutional investors and hedge funds have recently bought and sold shares of the company. Ariel Investments LLC grew its stake in Envista by 1.7% during the 2nd quarter. Ariel Investments LLC now owns 12,355,666 shares of the company’s stock worth $241,430,000 after buying an additional 210,921 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Envista by 0.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 9,628,460 shares of the company’s stock worth $209,036,000 after acquiring an additional 90,586 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Envista by 16.7% during the second quarter. Franklin Resources Inc. now owns 8,956,572 shares of the company’s stock valued at $175,011,000 after acquiring an additional 1,284,767 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Envista by 34.0% during the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after acquiring an additional 1,547,656 shares in the last quarter. Finally, Clarkston Capital Partners LLC raised its position in shares of Envista by 0.4% in the 2nd quarter. Clarkston Capital Partners LLC now owns 4,703,330 shares of the company’s stock valued at $91,903,000 after purchasing an additional 16,583 shares during the last quarter.
About Envista
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Featured Articles
- Five stocks we like better than Envista
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
